We Are Family: Why Recent Deals Show China And US Won’t Part Long
Recent deals linking Chinese and foreign firms indicate new and bolder views on China’s prospects for cutting-edge oncology and rare disease treatments, helped by recent regulatory changes, but a mix of factors is still at play, veteran executives say.
You may also be interested in...
As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.
Agency tells staff that it should refer patient questions about the law to the drug sponsor, while sponsors should be told to read the statute if they inquire about it.
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.